Proactive Investors - Run By Investors For Investors

VentriPoint Diagnostics reports that its new approved heart technology being used by internationally renowned pediatric cardiologist

Earlier this week, the firm said its VMS+ software had been approved for analyzing 3D echo images
VentriPoint Diagnostics reports that its new approved heart technology being used by internationally renowned pediatric cardiologist
The firm's tech is being used by a renowned pediatric cardiologist (not pictured)

Medtech group VentriPoint Diagnostics Ltd (CVE:VPT) gave another operational update on Tuesday, saying its VMS+ technology for the heart was now being used for analysis of the left ventricle as well as the right by an internationally renowned pediatric cardiologist in Germany.

As reported earlier this week, Ventripoint extended its reach into the heart imaging market as it revealed its VMS+ software had been approved for analyzing 3D echo images generated by any commercially available 3D echocardiography system.

READ: VentriPoint Diagnostics' heart monitoring tech further boosted by agreement with Canadian government

Renowned Dr Kai Thorsten Laser has now begun using the VMS+ software for 3-D echo analysis of the left ventricle at the HDZ NRW Heart and Diabetes Center in Germany, the firm said in a regulatory release Tuesday.

"We have experienced very positive results and accuracy using Ventripoint's VMS+ system on the right ventricle," said Dr Thorsten Laser.

"We now look forward to performing 3D analysis to validate accuracy of volumes of the left ventricle and in turn, improve cardiac patient care," he added.

Now that the company's software has been approved for all four chambers of the heart, the hospital will be using the Ventripoint VMS+ system for left ventricular volume analysis, particularly for pediatric patients.

There are many potential applications for this innovative technology, the firm says, which provides confidence in the volumetric measurements of patients with accuracy comparable to cardiac MRI.

Shares in Toronto were unchanged at $0.185.

Contact Giles Gwinnett at [email protected]

Follow Giles on Twitter @Gile74

View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Related Articles

Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020
Sativa
June 07 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has "delivered expeditiously on its investment promise to the market"
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use